Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aileron Therapeutics Q2 2024 GAAP EPS $(0.45) Misses $(0.42) Estimate; Cash Position $21.9M

Author: Benzinga Newsdesk | August 15, 2024 03:07am
Aileron Therapeutics (NASDAQ:ALRN) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.42) by 7.14 percent. This is a 15.38 percent decrease over losses of $(0.39) per share from the same period last year.

Posted In: ALRN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist